NCT01622504View on ClinicalTrials.gov

Naloxone Nasal Spray Pharmacokinetic Study

PHASE1UnknownINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

August 31, 2012

Conditions
Opioid Overdose
Interventions
DRUG

MVP005

2 mg single dose administered intranasally

DRUG

MVP005

4 mg single dose administered intranasally

DRUG

Naloxone hydrochloride solution for injection with mucosal atomization device

2 mg single dose administered intranasally

Trial Locations (1)

Unknown

International Pharmaceutical Research Center (IPRC), Amman

Sponsors

Lead Sponsor

Mitovie Pharma Ltd
All Listed Sponsors
lead

Mitovie Pharma Ltd

INDUSTRY